Corcept Therapeutics

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corcept Therapeutics reports robust earnings, navigates legal challenges for growth

Corcept Therapeutics demonstrated strong financial performance, stability, and strategic investments in key areas of its business.
While facing legal challenges and adapting to industry changes, the company capitalized on opportunities for growth and innovation.
Overall, Corcept's focus on clinical advancements and strategic investments positions it well for future success and expansion in the healthcare sector.

Corcept Therapeutics reports revenue growth, legal battles with Teva

Corcept Therapeutics delivered strong Q1 performance with revenue growth and a robust financial position.
The company faces challenges in managing expenses, legal battles, and sustaining R&D investments.
Opportunities lie in sales force expansion, clinical trials, and upcoming studies for growth and innovation.
Overall, Corcept's strategic focus on growth and legal defense positions it for future success in the market.

Corcept Therapeutics reports robust Q2 earnings and expands treatment reach

Corcept Therapeutics delivered strong financial performance, raised revenue guidance, and showcased progress in clinical development programs.
While facing legal challenges and market expansion complexities, the company's proactive strategies and positive trial results position it well for future growth.
Opportunities in partnerships, physician engagement, and broadening disease applications underscore Corcept's potential for continued success and impact in the healthcare industry.

Corcept Therapeutics excels in Q3, eyes growth in new markets

Corcept Therapeutics demonstrated robust financials, strategic wins in legal battles, and a focus on market expansion and product innovation.
While facing challenges in maintaining competitive positioning and navigating regulatory landscapes, the company is poised for growth.
With a strong performance in Q3 2023 and promising opportunities ahead, Corcept is well-positioned to capitalize on its strengths and drive future success.

Corcept Therapeutics reports robust Q4 revenue and diversifies pipeline

Corcept Therapeutics demonstrated strong financial performance in Q4 2023 with revenue growth and profitability.
The company's ongoing research and diversified pipeline position it well for future growth.
Challenges include legal disputes and market competition, but strategic planning and label expansions offer opportunities.
Overall, Corcept's financial stability, confidence in growth, and focus on treatment efficacy are key takeaways.

Corcept Therapeutics reports robust Q1 performance and eyes market expansion

Corcept Therapeutics delivered strong financial performance in Q1 2024, with revenue growth, increased net income, and raised revenue guidance.
The company's focus on innovative treatments for hypercortisolism and various cancers positions it well for future growth and market expansion.
While facing challenges like legal battles and operational complexity, Corcept remains optimistic about its pipeline and market potential.

Corcept Therapeutics reports strong Q2 performance amidst pipeline advancements

Corcept Therapeutics demonstrated robust financial performance and commercial growth in Q2 2024, supported by a strong cash position.
The company's pipeline strength was evident through positive study results for relacorilant and ongoing trials in various medical conditions.
While facing legal challenges and NDA submission delays, Corcept has opportunities to leverage its pipeline and market strategies for future success.

Corcept Therapeutics reports strong Q3 earnings and advances pipeline

Corcept Therapeutics delivered robust financial results, showing substantial revenue growth and profitability in Q3 2024. The company's pipeline progress and expanded revenue guidance underscore its strong market position and growth potential.
While facing legal challenges and complexities in clinical development, Corcept's strategic initiatives in multiple therapeutic areas and combination therapies position it well to capitalize on market opportunities and drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. It engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 18, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT).If you suffered losses exceeding $50,000 investing in Corcept stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...

Corcept Update

Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.

Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates

Corcept Therapeutics Incorporated. (NASDAQ:CORT ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Sean Maduck - Chief Commercial Officer Bill Guyer - Chief Development Officer Conference Call Participants Matt Kaplan - Ladenburg Chris Howerton - Jefferies Edward Nash - Canaccord Genuity Gregory Fraser - Truist Securities Arthur He - H.C.

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2022 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates

Pacira Pharmaceuticals

REGENXBIO

Now is a good time to take a closer look at these stocks.

3 Small-Cap Medical Stocks With Big Momentum

Amgen

Biogen

Harmony Biosciences Holdings

Incyte

Regeneron Pharmaceuticals

Bio-Techne

Biotech stocks were some of the best performers at the start of the pandemic. More recently, though, they've vastly underperformed the broader market.

7 Best Biotech Stocks to Build Your Portfolio

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 10, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT).If you suffered losses exceeding $50,000 investing in Corcept stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...

Corcept Shareholder Alert

Key Hires Bring Diverse Expertise to Commercial and Development Initiatives Key Hires Bring Diverse Expertise to Commercial and Development Initiatives

Corcept Therapeutics Announces Appointment of Three Senior Leaders

Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.

Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study

Data to be Available in Fourth Quarter 2022 Data to be Available in Fourth Quarter 2022

Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain

Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.

Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study

MENLO PARK, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today announced overall survival (“OS”) data from its 178-patient, randomized, controlled, Phase 2 study of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Corcept (CORT) Up 5.8% Since Last Earnings Report: Can It Continue?

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - March 16, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT).If you suffered losses exceeding $50,000 investing in Corcept stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...

Corcept Shareholder Update

Making medicines is a more reliable path to share price appreciation than memes.

3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu Coin

The stock price of Corcept Therapeutics (NASDAQ: CORT), a relatively small pharmaceuticals company with a market capitalization of $2.6 billion, focused on the treatment of severe metabolic, oncologic, and neuropsychiatric disorders, has seen a substantial rise of 25% in a month, while it is up 1.

Up 25% In A Month, Will Corcept Therapeutics Stock Continue Its Upward Trajectory?

Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.

Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q4 2021 Results - Earnings Call Transcript

Corcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates

MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021.

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update

Corcept (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Corcept (CORT) This Earnings Season?

MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call

Let's see if Corcept Therapeutics (CORT) stock is a good choice for value-oriented investors right now from multiple angles.

Is Corcept Therapeutics (CORT) a Solid Value Investors Stock?

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Robert S.

News for Corcept Therapeutics Stock (CORT)